Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression
β Scribed by Raffaella Lionetti; Giuseppe Tisone; Giampiero Palmieri; Cristiana Almerighi; Alessandra Anselmo; Laura Tariciotti; Ilaria Lenci; Linda De Luca; Andrea Monaco; Mario Angelico
- Book ID
- 119229600
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 153 KB
- Volume
- 42
- Category
- Article
- ISSN
- 1590-8658
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Determinants of progression to cirrhosis in hepatitis C virus (HCV) infection have been well described in the immunocompetent population but remain poorly defined in liver transplant (LT) recipients. This cohort study determines the factors contributing to the development of fibrosis and its rate of
Recurrence of hepatitis C virus (HCV) following liver transplantation (LT) is universal. A subset of these patients develop advanced fibrosis and cirrhosis and it is believed that this leads to increased posttransplantation mortality. The specific aims of this study were to determine the incidence o
Significant liver fibrosis (F >or= 2) and portal hypertension (hepatic venous pressure gradient [HVPG] >or= 6 mmHg) at 1 year after liver transplantation (LT) identify patients with severe hepatitis C recurrence. We evaluated whether repeated liver stiffness measurements (LSM) following LT can discr